Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)
NCT ID: NCT00163462
Last Updated: 2016-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
750 participants
INTERVENTIONAL
2004-10-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciclesonide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FEV1 50-90% of predicted
Exclusion Criteria
* COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function
* Respiratory tract infection or asthma exacerbation within the last 30 days prior to entry into the study
* History of life-threatening asthma
* Premature birth
* Current smoking
* Smoking history with either equal or more than 10 pack-years
* Pregnancy
* Intention to become pregnant during the course of the study
* Breast feeding
* Lack of safe contraception
6 Years
11 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca AstraZeneca
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Altana Pharma/Nycomed
Campinas - SP, , Brazil
Altana Pharma/Nycomed
Curitiba-PR, , Brazil
Altana Pharma/Nycomed
Florianópolis-SC, , Brazil
Altana Pharma/Nycomed
Porto Alegre-RS, , Brazil
Altana Pharma/Nycomed
Porto Alegre-RS, , Brazil
Altana Pharma/Nycomed
Rio de Janeiro-RJ, , Brazil
Altana Pharma/Nycomed
Salvador - Bahia, , Brazil
Altana Pharma/Nycomed
Santo André-SP, , Brazil
Altana Pharma/Nycomed
Sao Paulo - SP, , Brazil
Altana Pharma/Nycomed
Sao Paulo-SP, , Brazil
Altana Pharma/Nycomed
São Paulo-SP, , Brazil
Altana Pharma/Nycomed
São Paulo-SP, , Brazil
Altana Pharma/Nycomed
Frankfurt, , Germany
Altana Pharma/Nycomed
Gaißach Bei Bad Tölz, , Germany
Altana Pharma/Nycomed
Geesthacht, , Germany
Altana Pharma/Nycomed
Mainz, , Germany
Altana Pharma/Nycomed
München, , Germany
Altana Pharma/Nycomed
München, , Germany
Altana Pharma/Nycomed
Wesel, , Germany
Altana Pharma/Nycomed
Wiefelstede, , Germany
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Budapest, , Hungary
Altana Pharma/Nycomed
Debrecen, , Hungary
Altana Pharma/Nycomed
Jászberény, , Hungary
Altana Pharma/Nycomed
Miskolc, , Hungary
Altana Pharma/Nycomed
Mosdós, , Hungary
Altana Pharma/Nycomed
Pécs, , Hungary
Altana Pharma/Nycomed
Törökbálint, , Hungary
Altana Pharma/Nycomed
Inowrocław, , Poland
Altana Pharma/Nycomed
Lodz, , Poland
Altana Pharma/Nycomed
Lublin, , Poland
Altana Pharma/Nycomed
Poznan, , Poland
Altana Pharma/Nycomed
Rzeszów, , Poland
Altana Pharma/Nycomed
Warsaw, , Poland
Altana Pharma/Nycomed
Warsaw, , Poland
Altana Pharma/Nycomed
Zawadzkie, , Poland
Altana Pharma/Nycomed
Amadora, , Portugal
Altana Pharma/Nycomed
Faro, , Portugal
Altana Pharma/Nycomed
Guimarães, , Portugal
Altana Pharma/Nycomed
Lisbon, , Portugal
Altana Pharma/Nycomed
Lisbon, , Portugal
Altana Pharma/Nycomed
Lisbon, , Portugal
Altana Pharma/Nycomed
Matosinhos Municipality, , Portugal
Altana Pharma/Nycomed
Oliveira de Azeméis, , Portugal
Altana Pharma/Nycomed
Porto, , Portugal
Altana Pharma/Nycomed
Porto, , Portugal
Altana Pharma/Nycomed
Setúbal, , Portugal
Altana Pharma/Nycomed
Viana do Castelo, , Portugal
Altana Pharma/Nycomed
Vila Nova de Gaia, , Portugal
Altana Pharma/Nycomed
Bellville - Cape Town -, , South Africa
Altana Pharma/Nycomed
Cape Town, , South Africa
Altana Pharma/Nycomed
Morningside, Sandton, , South Africa
Altana Pharma/Nycomed
Mowbray, Cape Town, , South Africa
Altana Pharma/Nycomed
Panorama / RSA-Cape Town, , South Africa
Altana Pharma/Nycomed
Westville, , South Africa
Altana Pharma/Nycomed
Wynberg, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BY9010-MI-206-RDS-2006-09-01.pdf
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BY9010/M1-206
Identifier Type: -
Identifier Source: org_study_id